Innovative Approaches to Treat Obesity and Related Indications
Brite Therapeutics, Inc. is developing novel treatments for metabolic-related disorders by targeting brite/brown fat cells and by developing a novel combination of repurposed drugs (aka Brite-1).
Cutting-edge drug combinations to treat obesity and related metabolic co-morbidities, such as fatty liver, diabetes or hyperlipidemia.
Focused approach to identify and characterize drugs and their targets which regulate thermogenesis in brown and brite fat cells.
Seeking partnerships to discover drugs using brite/brown fat cells and develop drug combinations through clinical trials for obesity.
PIPELINE
Novel Brite/Brown Fat Cell Biology
Brite Therapeutics, Inc. is exploring brite and brown fat cell biology and methods to enhance progenitor cell recruitment, differentiation into brown and brite fat cells, and increase energy expenditure in these cells. By targeting these cells we expect to improve metabolism by stimulating thermogenesis, fatty acid oxidation, and lipid and carbohydrate metabolism.
Novel Combination of Repurposed Drugs
Brite Therapeutics Inc. is progressing a novel drug combination, referred to as Brite-1, into clinical trials for treating obesity, fatty liver disease, and related metabolic indications. Significant preclinical, clinical and genetic validation exists for each individual drug. The treatment targets unique mechanisms distinct from GLP-1 and may be used as a GLP-1/incretin add-on. This novel drug combination targets both food intake and energy expenditure and was selected for its potential long term use in weight maintenance.
